Meeting
2021 Genitourinary Cancers Symposium
Association of health-related quality of life (HRQOL) variations with biological biomarkers for patients with metastatic castrate-resistant prostate cancer (MCRPC) treated by abiraterone/prednisone combination or prednisone.
Authors
Morgan Goujon
Department of Medical Oncology, University Hospital, Besançon, France
Morgan Goujon , Amelie Anota , Alexandre Frontczak , Emilie Charton , Tristan Maurina , Hamadi Almotlak , Thierry Nguyen , Calcagno Fabien , Ulrich Stein , Guillaume Mouillet , Antoine Thiery-Vuillemin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 54)
DOI
10.1200/JCO.2021.39.6_suppl.54
Abstract #
54
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.
First Author: Bobby Chi-Hung Liaw
Poster
2023 ASCO Annual Meeting
A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
First Author: Daniel J. George
Poster
2016 Genitourinary Cancers Symposium
Genomic and imaging biomarkers associated with cabozantinib therapy in metastatic castrate resistant prostate cancer (mCRPC).
First Author: Ulka N. Vaishampayan
Poster
2015 ASCO Annual Meeting
A molecular and clinico-pathological model for predicting abiraterone acetate/prednisone (AA/P) efficacy in metastatic castrate resistant prostate cancer (mCRPC).
First Author: Manish Kohli